Plant Name: Magnolia officinalis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.253E-11 | 2.117E-07 | CA12, CA2, CA3, CA4, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.762E-09 | 5.468E-06 | CA12, CA2, CA3, CA4, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.886E-09 | 1.227E-05 | CA12, CA2, CA3, CA4, CA9 |
| BP | GO:0065007; biological regulation | GO:0065008; regulation of biological quality | 5.600E-08 | 6.775E-05 | ABCB1, ALOX15, CA12, CA2, CASP1, CNR1, CNR2, CYP3A4, FABP3, FABP4, GLA, HIF1A, MAPK1, MAPT, PPARA, PPARD, TLR2, TRPV1, XDH |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 6.705E-08 | 7.684E-05 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0051001; negative regulation of nitric-oxide synthase activity | 1.304E-07 | 1.305E-04 | CNR1, CNR2, GLA |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 1.318E-07 | 1.305E-04 | ABCB1, CA3, CA9, CASP1, CNR1, CNR2, FABP3, MAPK1, TLR2, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.304E-06 | 7.472E-04 | CA2, CA9, CASP1, CNR1, CNR2, FABP3, PPARD, RXRA, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0050727; regulation of inflammatory response | 2.168E-06 | 1.152E-03 | CASP1, CNR1, CNR2, FABP4, PPARA, PPARD, TLR2 |
| BP | GO:0002376; immune system process | GO:0001774; microglial cell activation | 2.507E-06 | 1.300E-03 | MAPT, TLR2, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 3.048E-06 | 1.537E-03 | CASP1, HIF1A, LMNA, PPARA, PPARD, TLR2 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 6.829E-06 | 3.035E-03 | GLA, HIF1A, MAPT, TRPV1, XDH |
| MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 7.471E-06 | 3.190E-03 | CNR1, CNR2 |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 8.698E-06 | 3.573E-03 | CASP1, CASP7, MAPT, XDH |
| BP | GO:0032501; multicellular organismal process | GO:0001816; cytokine production | 9.128E-06 | 3.681E-03 | CASP1, FABP4, HIF1A, TLR2 |
| BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 1.193E-05 | 4.331E-03 | CNR1, FABP3, PPARA |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 1.416E-05 | 4.973E-03 | CA2, CA9, CASP1, CASP7, CNR1, MAPK1, TLR2, TRPV1 |
| BP | GO:0065007; biological regulation | GO:0065009; regulation of molecular function | 1.451E-05 | 5.015E-03 | ABCB1, CASP1, CASP7, CNR1, CNR2, FABP4, GLA, HIF1A, MAPK1, MAPT, PPARA, RAB9A, TLR2, TRPV1, TSHR, XDH |
| BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 1.493E-05 | 5.019E-03 | CNR1, CNR2 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.632E-05 | 5.212E-03 | ALOX15, ALOX5, TLR2 |
| BP | GO:0023052; signaling | GO:0032228; regulation of synaptic transmission, GABAergic | 1.799E-05 | 5.596E-03 | CA2, CNR1, CNR2 |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 1.845E-05 | 5.657E-03 | ALOX15, CASP1, FABP4, HIF1A, MAPK1, TRPV1 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.168E-05 | 8.515E-03 | CA12, CA2, CA3, CA4, CA9, PPARA, PPARD, RXRA |
| BP | GO:0007610; behavior | GO:0007611; learning or memory | 3.352E-05 | 8.901E-03 | CNR1, HIF1A, MAPK1, MAPT, TLR2 |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 3.724E-05 | 9.770E-03 | ALOX15, ALOX5 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.048E-11 | 1.446E-09 | FABP2; FABP3; RXRA; FABP4; FABP5; PPARA; PPARD |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.894E-11 | 2.687E-09 | CA12; CA3; CA2; CA4; CA9 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.267E-06 | 1.963E-04 | ABCB1; RXRA; CA2; CYP3A4 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 8.376E-05 | 2.890E-03 | CASP7; CASP1; TLR2 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.111E-04 | 5.827E-03 | CASP7; CASP1; MAPK1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.855E-04 | 1.058E-02 | ALOX5; ALOX15; MAPK1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 7.977E-04 | 1.058E-02 | ALOX5; MAPK1; TLR2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.977E-04 | 1.058E-02 | RXRA; MAPK1; HIF1A |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 8.438E-04 | 1.058E-02 | CNR2; CNR1; TRPV1; TSHR |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.307E-03 | 1.289E-02 | CASP7; LMNA; MAPK1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.128E-03 | 1.197E-02 | RXRA; MAPK1; PPARA |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.624E-03 | 1.494E-02 | CASP7; RXRA; PPARA |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.149E-03 | 2.131E-02 | RXRA; MAPK1; HIF1A; PPARD |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.764E-04 | 1.058E-02 | CA2; CA4 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.202E-03 | 1.872E-02 | CASP7; MAPK1; MAPT |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 9.197E-04 | 1.058E-02 | RXRA; MAPK1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.756E-03 | 2.148E-02 | MAPK1; HIF1A; TLR2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.552E-03 | 2.131E-02 | MAPK1; PPARA; TSHR |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.399E-03 | 2.131E-02 | RXRA; MAPK1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.197E-04 | 1.058E-02 | ALOX15; CYP3A4 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 3.399E-03 | 2.131E-02 | FABP4; TSHR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.519E-03 | 2.131E-02 | MAPK1; PPARD |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.306E-03 | 1.872E-02 | CYP3A4; XDH |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 3.891E-03 | 2.148E-02 | MAPK1; HIF1A |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.519E-03 | 2.131E-02 | CASP1; MAPK1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 4.689E-03 | 2.380E-02 | MAPK1; HIF1A |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.149E-03 | 2.202E-02 | ALOX5; ALOX15 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.828E-03 | 2.380E-02 | MAPK1; HIF1A |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 5.706E-03 | 2.625E-02 | MAPK1; TLR2 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 5.259E-03 | 2.502E-02 | RXRA; PPARA |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 1.067E-02 | 4.327E-02 | CNR1; MAPK1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.067E-02 | 4.327E-02 | MAPK1; HIF1A |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.108E-02 | 4.327E-02 | MAPK1; HIF1A |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.171E-02 | 4.366E-02 | MAPK1; TLR2 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.256E-02 | 4.562E-02 | CASP7; MAPK1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.129E-02 | 4.327E-02 | MAPK1; TLR2 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 7.837E-03 | 3.380E-02 | CASP1; MAPK1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.727E-03 | 3.380E-02 | XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CNR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| NA: NA | Esophagus sensitivity | NA | TRPV1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | CNR1; PPARD |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia | F50.0-F50.1 | CNR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | CNR1 |
| C00-D49: Neoplasms | Cutaneous T-cell lymphoma | C84.0, C84.1 | RXRA |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | CNR1; CNR1; CNR1; CNR1; CNR1; CNR1; PPARD; PPARD |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| NA: NA | Dyslipidemia | NA | PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR1; TRPV1; CNR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | CNR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | CNR1; PPARD; MAPT |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | CNR1; CNR1; CNR1 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; CNR2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CNR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR1; TRPV1; TRPV1; CNR2 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | CNR1; ABCB1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; TRPV1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | CNR1; CNR1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | CNR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chemotherapy-induced nausea | R11 | CNR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | CNR1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | CNR1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; ABCB1; CA9; MAPK1; TLR2 |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | CNR1; TRPV1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; ABCB1; CA9; MAPK1; TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; CASP1; CNR2 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CNR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; TRPV1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; PPARD |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; TRPV1; CNR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | CNR1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | CNR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |